Please login to the form below

Not currently logged in
Email:
Password:

Partner for Sanofi on pneumonia KB001

KaloBios has announced an agreement with Sanofi Pasteur for the development of KB001 for Pseudomonas aeruginosa (Pa) infections

KaloBios Pharmaceuticals has announced an agreement with Sanofi Pasteur for the development and commercialisation of KB001 for the treatment or prevention of Pseudomonas aeruginosa (Pa) infections.

Sanofi Pasteur (the vaccines division of the sanofi-aventis Group), will be responsible for the development and commercialisation of KB001, an investigational new biologic, and initially focus on hospital indications, including the prevention of Pa pneumonias in mechanically ventilated patients.

KaloBios will focus on developing and commercialising KB001 for use in treating patients with cystic fibrosis and bronchiectasis, an obstructive lung disease aggravated by bacterial infections.

Under the terms of the agreement, KaloBios will receive an upfront payment of $35m from Sanofi Pasteur, plus development, regulatory and commercial milestones for a potential further $255m, as well as royalties on eventual product sales. Sanofi Pasteur also has the option to acquire commercial rights to KaloBios' indications for KB001 outside the US and co-promotion rights in the US.

"Hospital-based pneumonias, especially those associated with mechanically ventilated patients in the ICU, are a life-threatening complication that can significantly increase mortality and morbidity as well as add tens of thousands of dollars to the cost of a hospital stay," said Dr Tillman Pearce, chief medical officer of KaloBios.

"KB001's novel mechanism of action against Pa provides a unique means of fighting these infections, which are often resistant to antibiotic therapies. We also think this novel mechanism could have a significant impact on Pseudomonas aeruginosa infections in cystic fibrosis patients as well."

11th January 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics